These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24361227)

  • 1. Genetic polymorphisms of SLC28A3, SLC29A1 and RRM1 predict clinical outcome in patients with metastatic breast cancer receiving gemcitabine plus paclitaxel chemotherapy.
    Lee SY; Im SA; Park YH; Woo SY; Kim S; Choi MK; Chang W; Ahn JS; Im YH
    Eur J Cancer; 2014 Mar; 50(4):698-705. PubMed ID: 24361227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential role of CMPK1, SLC29A1, and TLE4 polymorphisms in gemcitabine-based chemotherapy in HER2-negative metastatic breast cancer patients: pharmacogenetic study results from the prospective randomized phase II study of eribulin plus gemcitabine versus paclitaxel plus gemcitabine (KCSG-BR-13-11).
    Cho EH; Kim JY; Im SA; Jung KH; Sohn J; Lee KS; Chae YS; Lee KH; Kim JH; Jang JH; Ahn JH; Park MS; Lee SY; Park YH
    ESMO Open; 2021 Oct; 6(5):100236. PubMed ID: 34438242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenomic study of gemcitabine efficacy in patients with metastatic pancreatic cancer: A multicenter, prospective, observational cohort study (GENESECT study).
    Hatori M; Tsuji D; Suzuki K; Yokokawa T; Kawakami K; Moriyama R; Osada-Tsuchiya M; Otake A; Nakao M; Yano T; Arakawa Y; Matsuo K; Ohashi Y; Sakata Y; Kogure Y; Tamaki S; Wada A; Taki Y; Sasahira N; Ishii H; Yamaguchi M; Itoh K
    Cancer; 2024 Sep; 130(17):2988-2999. PubMed ID: 38682652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.
    Park YH; Im SA; Kim SB; Sohn JH; Lee KS; Chae YS; Lee KH; Kim JH; Im YH; Kim JY; Kim TY; Lee KH; Ahn JH; Kim GM; Park IH; Lee SJ; Han HS; Kim SH; Jung KH;
    Eur J Cancer; 2017 Nov; 86():385-393. PubMed ID: 29100193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine.
    Jørgensen CL; Ejlertsen B; Bjerre KD; Balslev E; Nielsen DL; Nielsen KV
    BMC Cancer; 2013 Nov; 13():541. PubMed ID: 24215511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytidine Deaminase as a Molecular Predictor of Gemcitabine Response in Patients with Biliary Tract Cancer.
    Yoon KA; Woo SM; Hong EK; Jung MK; Park WS; Bae K; Han SS; Kim TH; Koh YH; Park SJ; Lee WJ
    Oncology; 2015; 89(6):345-50. PubMed ID: 26418006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RRM1 single nucleotide polymorphism -37C-->A correlates with progression-free survival in NSCLC patients after gemcitabine-based chemotherapy.
    Dong S; Guo AL; Chen ZH; Wang Z; Zhang XC; Huang Y; Xie Z; Yan HH; Cheng H; Wu YL
    J Hematol Oncol; 2010 Mar; 3():10. PubMed ID: 20226083
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II trial of customized first line chemotherapy according to ERCC1 and RRM1 SNPs in patients with advanced non-small-cell lung cancer.
    Mazzoni F; Cecere FL; Meoni G; Giuliani C; Boni L; Camerini A; Lucchesi S; Martella F; Amoroso D; Lucherini E; Torricelli F; Di Costanzo F
    Lung Cancer; 2013 Nov; 82(2):288-93. PubMed ID: 24045016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An association between RRM1 haplotype and gemcitabine-induced neutropenia in breast cancer patients.
    Rha SY; Jeung HC; Choi YH; Yang WI; Yoo JH; Kim BS; Roh JK; Chung HC
    Oncologist; 2007 Jun; 12(6):622-30. PubMed ID: 17602053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of gemcitabine pathway polymorphisms on treatment outcome in patients with malignant mesothelioma.
    Erčulj N; Kovač V; Hmeljak J; Franko A; Dodič-Fikfak M; Dolžan V
    Pharmacogenet Genomics; 2012 Jan; 22(1):58-68. PubMed ID: 22134350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase III, multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy: KCSG-BR07-02.
    Park YH; Jung KH; Im SA; Sohn JH; Ro J; Ahn JH; Kim SB; Nam BH; Oh DY; Han SW; Lee S; Park IH; Lee KS; Kim JH; Kang SY; Lee MH; Park HS; Ahn JS; Im YH
    J Clin Oncol; 2013 May; 31(14):1732-9. PubMed ID: 23569309
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient.
    Mlak R; Krawczyk P; Ciesielka M; Kozioł P; Homa I; Powrózek T; Prendecka M; Milanowski J; Małecka-Massalska T
    Clin Transl Oncol; 2016 Sep; 18(9):915-24. PubMed ID: 26650486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of nucleoside transporters, deoxycitidine kinase, ribonucleotide reductase regulatory subunits, and gemcitabine catabolic enzymes in primary ovarian cancer.
    Ferrandina G; Mey V; Nannizzi S; Ricciardi S; Petrillo M; Ferlini C; Danesi R; Scambia G; Del Tacca M
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):679-86. PubMed ID: 19639316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer.
    Brufsky A; Hoelzer K; Beck T; Whorf R; Keaton M; Nadella P; Krill-Jackson E; Kroener J; Middleman E; Frontiera M; Paul D; Panella T; Bromund J; Zhao L; Orlando M; Tai F; Marciniak MD; Obasaju C; Hainsworth J
    Clin Breast Cancer; 2011 Aug; 11(4):211-20. PubMed ID: 21723792
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection.
    Nakagawa N; Murakami Y; Uemura K; Sudo T; Hashimoto Y; Kondo N; Sueda T
    Surgery; 2013 Apr; 153(4):565-75. PubMed ID: 23253379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ribonucleotide reductase M1 (RRM1) 2464G>A polymorphism shows an association with gemcitabine chemosensitivity in cancer cell lines.
    Kwon WS; Rha SY; Choi YH; Lee JO; Park KH; Jung JJ; Kim TS; Jeung HC; Chung HC
    Pharmacogenet Genomics; 2006 Jun; 16(6):429-38. PubMed ID: 16708051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of GSTP1 and RRM1 Polymorphisms with the Response and Toxicity of Gemcitabine-cisplatin Combination Chemotherapy in Chinese Patients with Non-small Cell Lung Cancer.
    Yuan ZJ; Zhou WW; Liu W; Wu BP; Zhao J; Wu W; He Y; Yang S; Su J; Luo Y
    Asian Pac J Cancer Prev; 2015; 16(10):4347-51. PubMed ID: 26028097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer.
    Zhang GB; Chen J; Wang LR; Li J; Li MW; Xu N; Wang Y; Shentu JZ
    Cancer Chemother Pharmacol; 2012 May; 69(5):1277-87. PubMed ID: 22302408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Caveolin-1 expression predicts efficacy of weekly nab-paclitaxel plus gemcitabine for metastatic breast cancer in the phase II clinical trial.
    Zhao Y; Lv F; Chen S; Wang Z; Zhang J; Zhang S; Cao J; Wang L; Cao E; Wang B; Hu X
    BMC Cancer; 2018 Oct; 18(1):1019. PubMed ID: 30348118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive value of ERCC1 and RRM1 gene single-nucleotide polymorphisms for first-line platinum- and gemcitabine-based chemotherapy in non-small cell lung cancer patients.
    Mlak R; Krawczyk P; Ramlau R; Kalinka-Warzocha E; Wasylecka-Morawiec M; Wojas-Krawczyk K; Kucharczyk T; Homa I; Kozioł P; Ciesielka M; Chudziak D; Milanowski J
    Oncol Rep; 2013 Nov; 30(5):2385-98. PubMed ID: 23982437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.